26 articles with Elysium Health
Elysium Health™ Announces Research at Mayo Clinic to Study Associations Between NAD+ Levels and Senescent Cell Burden and Develop Epigenetic Measures of Cellular Senescence
Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced the initiation of research at Mayo Clinic to study associations between circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults and senescent cell burden, and to develop novel epigenetic measures of cellular senescence.
Elysium Health™ Announces New Research Initiative in Partnership With the University of Oxford in Connection With the Landmark INTERBIO-21st Study
Elysium Health, Inc. has entered into a material transfer agreement with the University of Oxford to analyze the DNA methylation patterns of 2,500 umbilical cord blood samples from the landmark INTERBIO-21st Study.
Elysium Health™ Announces Research Partnership with the University of Oxford for the Purpose of Developing Epigenetic Measures of Brain Aging and Health
Elysium Health, Inc.™, a leading life sciences company focused on aging research, has entered into a material transfer agreement with the University of Oxford to examine hundreds of samples from the VITACOG study to develop epigenetic measures of brain aging and health.
12/21/2020Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Elysium Health™ Announces Initiation of Phase II Clinical Trial at Mayo Clinic to Evaluate BASIS™ for Prevention of Acute Kidney Injury After Cardiac Surgery
Elysium Health, Inc.,TM a life sciences company developing clinically validated health products based on aging research, announced the initiation of a Phase II clinical trial at Mayo Clinic to evaluate the efficacy of BASISTM for the prevention of acute kidney injury in patients that have undergone a cardiac surgery.
The long-term brain health supplement developed in partnership with the University of Oxford
1/13/2020The first full business week of the new year began with plenty of clinical trial news. Here’s a look.
Elysium Health™ Announces Clinical Trial to Study Correlations Between Epigenetic Aging and Nicotinamide Adenine Dinucleotide (NAD+) Levels in Healthy Adults
Elysium Health, Inc.™, a life sciences company developing clinically validated health products based on advancements in scientific research, today announced the initiation of a clinical trial at Duke Clinical Research Institute to study correlations between biological age and circulating NAD+ levels in healthy adults, in addition to other clinical biomarkers that have been implicated in aging.
Joined by Mayo Clinic Ventures, WTI, General Catalyst, Morningside Ventures, and Breyer Capital
Elysium Health™ Announces Clinical Trial to Explore the Effect of Basis™ on Liver Fat Accumulation in Healthy Adults with Fatty Liver (NAFL)
All of these biomarkers are also conditions that are associated with excessive accumulation of liver fat, indicating that fatty liver may be regarded as the hepatic manifestation of metabolic syndrome.
A powerful measure of overall health and wellness that enables customers to test their cumulative rate of aging and biological age--the average age at which their body is expected to perform
With a shared commitment to innovation, the alliance aims to support a healthier humanity--starting with healthier guests
Elysium Health™ Announces Initiation of Clinical Trial to Explore the Effects of Basis™ and High-Intensity Interval Training (HIIT) on Muscle Metabolism and Exercise Performance
Elysium Health, Inc.,™ a life sciences company developing clinically validated health products based on aging research, today announced the initiation of a clinical trial at University of Exeter, UK to explore the effects of Basis™ and high-intensity interval training (HIIT) on muscle metabolism and exercise in 18 – 35 year-olds
2/11/2019There has been recent optimism—and possibly hype—over so-called NAD boosters. Kaiser Health News (KHN) recently reported on Harvard University researcher David Sinclair, who is taking his own research product, a supplement that boosts nicotinamide adenine dinucleotide (NAD), a cofactor found in a...
The Good Housekeeping Institute Partners with Elysium HealthTM to Launch ‘GH Wellness Lab’ at Hearst Tower
The Newest Lab Within the Good Housekeeping Institute Will Test and Identify Products that Prioritize Safety and Efficacy to Advance the Health and Wellness Industry
ChromaDex to move forward with patent infringement action, following unsuccessful challenge by Elysium Health during Inter Partes Review (IPR)
Elysium Health, Inc.,™ responded today to the baseless allegations by ChromaDex and Dartmouth College that it had infringed on two patents.
Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard
Elysium Health, Inc.™ has entered into an exclusive license agreement with Mayo Clinic and Harvard University.
Elysium Health, Inc.,™ announced that its cellular health product Basis is NSF International Certified for Sport.
Industry innovator developing clinically proven health products adds award-winning behavioral economist Daniel Kahneman, Ph.D., to its scientific advisory board and healthcare leader Gary Gottlieb, M.D., to its board of directors.